TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy

Tet methylcytosine dioxygenase 2 (TET2) is one of the most frequently mutated genes in myelodysplastic syndrome (MDS). TET2 is known to involve a demethylation process, and the loss of TET2 is thought to cause DNA hypermethylation. Loss of TET2 function is known to be caused by genetic mutations and...

Full description

Bibliographic Details
Main Authors: Jina Yun, Young Sok Ji, Geum Ha Jang, Sung Hee Lim, Se Hyung Kim, Chan Kyu Kim, Sang Byung Bae, Jong Ho Won, Seong Kyu Park
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Current Issues in Molecular Biology
Subjects:
TET2
miR-22
hypomethylating therapy
myelodysplastic syndrome (MDS)
hypermethylation
cytogenetic abnormality
Online Access:https://www.mdpi.com/1467-3045/43/2/65

Internet

https://www.mdpi.com/1467-3045/43/2/65

Similar Items